News and events

All year   | 2024 | 2023 | 2022 | 2021 | 2020 | 2019
04
Dec
2023
-

AMASS version 3.0 (BETA) Build 3022 is now available to download



The current version of the AMASS application provides updates including.



1. Add “Annex C: Cluster signals”. This supplementary report shows the information of potential clusters which are identified using the SatScan (www.satscan.org).
2. Add processed data files in the folder “Report_with_patient_identifiers” so that users can use the processed data file (e.g. deduplicated and merged data files for each AMR pathogen) for any further analysis on internal use.
3. Enterococcus faecalis and E. faecium were explicitly included in the pathogens under the survey (while Enterococcus spp. was used in the AMASS version 2.0)
4. Add a few antibiotics in the list of antibiotics for a few pathogens under the survey.
5. Use only Python rather than R + Python (as used in the AMASS version 2.0).
6. Include patients who have missing discharge dates in the analysis by truncating the day at risk using the last date of specimen date in the data set (e.g. a patient who was admitted on 30 Dec 2023, had blood specimen collected for culture on 31 Dec 2023, and were still in the hospital on 10 Jan 2024. Then, the microbiology data file and hospital admission date file were exported on 10 Jan 2024 for the data of year 2023 [specimen dates and hospital admission dates from 1 Jan 2023 to 31 Jan 2023]. This patient would be included in the analysis, assuming that the days at risk of BSI was from 30 Dec to 31 Dec 2023, and the specimen collected on 31 Dec 2023 would be included in the analysis. In the AMASS version 2.0, this patient would not be included in the analysis as the code for truncation among patients who were not discharged was not included in the AMASS version 2.0).


10
Jan
2023
-

The third workshop for training the trainer in Thailand


AMASS version 2

AMASS team, in collaboration with the ministry of Public Health Thailand, organized the second online workshop. This section is the face-to-face meeting. We have discussion the cumulative antibiogram report from each hospital from the AMASS.